Various clinical presentations of uveitis associated with durvalumab treatment

Abstract

Background Immune checkpoint inhibitors (ICI) are becoming increasingly common in treating several cancer types. Durvalumab is a human IgG1 monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80 and has recently been approved for the treatment of extensive-stage small-cell lung cancer (ES-SCLC) and locally advanced unresectable (NSCLC). The present review aimed to analyse immune-mediated uveitis, secondary to durvalumab treatment, through a review of the literature and a presentation of two clinical cases. Patients and methods A literature review using PubMed search was conducted to identify cases of uveitis secondary to durvalumab and cases of uveitis with optic disc oedema secondary to ICI use that were reported prior to November 14, 2021. Additionally, we report two cases of uveitis consequent on durvalumab treatment. Results Five cases of uveitis secondary to durvalumab use were identified in the literature. Anterior, posterior uveitis and vasculitis were reported. Additionally, we present a case of bilateral intermediate uveitis with bilateral optic disc oedema and a case of bilateral posterior uveitis. Our further search revealed 12 cases of uveitis with optic disc oedema secondary to ICI use, with the majority of cases reported secondary to PD-1 inhibitors. Conclusions Rarely reported, uveitis secondary to durvalumab can present various clinical pictures and requires a thorough diagnostic workup. Once the diagnosis is established, treatment, commonly with a local or systemic corticosteroid, should be adapted to the severity of the inflammation.

Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application

“…Trials on avelumab or talazoparib plus binimetinib in mPDAC have shown promising additive or synergistic antitumor activity. Durvalumab is another humanized IgG1 monoclonal antibody ( 73 ) that targets PD-L1 and activates anti-tumor immunity by blocking the interaction between PD-L1 and its receptor, PD-1. It was first approved by the FDA in 2017 for the treatment of locally advanced or metastatic urothelial carcinoma ( 74 ) and stage III unresectable non-small cell lung cancer ( 75 ).…”